TRIM25 and prostate adenocarcinoma: To further validate the relationship between TRIM25 and CIC, differential expression analysis was performed using the TCGA BRCA cohort comparing samples with TRIM25 amplification versus samples with copy number neutral TRIM25. A total of 2789 DE genes were identified (FDR < 0.01, fold change > 1.5; Additional file 13: Table S6A) which were then compared to previously identified DE genes in TCGA type II low-grade glioma (type II LGG, n = 1538), prostate adenocarcinoma (PRAD, n = 842), and stomach adenocarcinoma (STAD, n = 3223) with CIC copy number loss [25], expecting directional concordance.